Mirum Pharmaceuticals Ownership
| MIRM Stock | USD 47.02 0.85 1.78% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 48 M | Current Value 48 M | Avarage Shares Outstanding 30.6 M | Quarterly Volatility 12.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Mirum |
Mirum Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.85. Mirum Pharmaceuticals had not issued any dividends in recent years. Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California. Mirum Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 171 people. To find out more about Mirum Pharmaceuticals contact Christopher Peetz at (650) 667-4085 or learn more at https://www.mirumpharma.com.Mirum Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mirum Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mirum Pharmaceuticals backward and forwards among themselves. Mirum Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Mirum Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 943.3 K | Clearbridge Advisors, Llc | 2024-12-31 | 907.3 K | Pictet Asset Manangement Sa | 2024-12-31 | 860.1 K | Lord, Abbett & Co Llc | 2024-12-31 | 782.4 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 758.4 K | Nuveen Asset Management, Llc | 2024-12-31 | 722.2 K | Polar Capital Holdings Plc | 2024-12-31 | 675 K | Avidity Partners Management Lp | 2024-12-31 | 666.2 K | Franklin Resources Inc | 2024-12-31 | 590.7 K | Hhg Plc | 2024-12-31 | 4.6 M | Blackrock Inc | 2024-12-31 | 3.4 M |
Mirum Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mirum Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mirum Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mirum Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mirum Pharmaceuticals Outstanding Bonds
Mirum Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mirum Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mirum bonds can be classified according to their maturity, which is the date when Mirum Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MISCMK 375 06 APR 27 Corp BondUS60475DAB73 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Mirum Pharmaceuticals Corporate Filings
F4 | 19th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.85) | Revenue Per Share | Quarterly Revenue Growth 0.429 | Return On Assets | Return On Equity |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.